| Name | AG881 |
|---|---|
| Synonyms | Vorasidenib |
| Description | Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor. |
|---|---|
| Related Catalog | |
| Target |
IDH[1] |
| In Vitro | Vorasidenib has recently entered phase 1 clinical trials in hematologic (NCT02492737) and solid malignancies (NCT02481154) in patients with either an IDH1 or an IDH2 mutation. Preclinical studies have suggested that Vorasidenib fully penetrates the blood-brain barrier and may be a more effective option for patients with IDH1/2 mutated glioma[1]. |
| References |
| Molecular Formula | C14H13ClF6N6 |
|---|---|
| Molecular Weight | 414.74 |
| Storage condition | -20℃ |